Robust new app in clinical trials may help with concussion diagnois

NORMAL - Miami Dolphins quarterback Tua Tagovailoa recently suffered his third confirmed concussion in 25 months – just another reminder that football and other contact sports pose the threat of a traumatic brain injury. Research indicates it’s important to accurately and immediately diagnose a concussion because the consequences of misdiagnosis or faulty management can lead to major disability or death.

Illinois State University senior Cyerra Hibbert knows about concussions. She’s had multiple ones while playing soccer in high school and at ISU, the most recent just a month ago. Hibbert is one of the first athletes to test a new FlightPath concussion app. The lead app developer is *Adam Cross, MD, a pediatric hospitalist and clinical informaticist for OSF HealthCare and director of the OSF Children’s Innovation Lab at Jump Simulation & Education Center in Peoria, Illinois. He is working with co-lead Inki Kim, of the Health Care Engineering Systems Center at the Grainger College of Engineering at the University of Illinois Urbana-Champaign.

The concussion assessment app is a grant-funded project through Jump ARCHES, a research collaborative that partners teams of clinicians and engineers working together to improve patient outcomes and reduce health care costs. The FlightPath app is being tested at Illinois State, Illinois Wesleyan and Bradley Universities as part of a clinical trial and research coalition. Hibbert used the FlightPath app after receiving instructions from her athletic trainer six days after she received a blow to the head during a game.


Cyerra Hibbert has suffered multiple concussions while playing soccer in high school and for the ISU Redbirds. Hibbert is one of the first athletes to test a new FlightPath concussion app.

Photo provided

Hibbert was able to finish the test. It only takes about two minutes to collect more than a million data points as a person tries to catch a hummingbird within a 3D space on a screen.

“After a while it did bring a little confusion or if I wasn’t aware of where the bird flew on or off the screen, that did trick a little bit of my memory and concentration skills, so I do think it’s definitely approachable," Hibbert explains. “It’s definitely doable. I think just based on your outcome will determine where you are in your concussion level.”

Photo provided
Dr. Adam Cross

Dr. Cross says the single biggest risk factor for prolonged time to recovery is delayed diagnosis, so FlightPath is his answer with its ability to diagnose a concussion within minutes. His research team has done some internal testing.

“Regarding how well it detects differences in impairments with people – how well they can determine if someone is functioning, acting appropriately, or if there's if there's something else going on. The challenge has been really doing that with individuals that have true concussion,” says Dr. Cross.

Athletes with a suspected concussion are challenged by FlightPath to walk in their environment while trying to keep a hummingbird in a bubble on the screen.

“The players themselves are trying out this app while concussed after having been consented earlier on in the year so that we can get data around how they perform with this app while concussed versus not concussed, and comparing that to the normal, typical present-day evaluation techniques that the trainers perform.”

Photo provided
Dr. Karan Rai

Dr. Cross stresses, right now, the clinical trial does not involve trainers using the app to help make decisions. He says the research is not that far along and data collection needs to happen first. But, Karan Rai, MD, a sports medicine physician with OSF HealthCare who also serves as the team doctor for ISU Athletics, says eventually, the data from FlightPath could help beyond diagnosis.

“It in turn can help us with making prognoses, coming up with recovery timelines, implementing certain vestibular therapy. Other than diagnostic purposes, we can extrapolate that data to help us come up with a better treatment plan as well.”

Takes the pressure off

Both Hibbert and Dr. Rai are excited to be part of what they consider ground-breaking research that has the potential for helping athletes in the future. Hibbert, who plans to go into medical sales, says it’s helpful to have an objective tool for an evaluation. She thinks it takes the pressure off athletes.

“Because as athletes, we’re always eager to be on the field or play the game and to have that mindset to be better and get back on your feet as quickly as you can. I think this app will allow you to really settle and to really take your time with your symptoms.”

The clinical trial is looking at whether FlightPath can do as good or better as traditional methods in diagnosing a concussion. So far, Dr. Rai says nearly 15 athletes who have suffered a concussion have completed a FlightPath assessment and it’s been performing well.

“Results are early so far but in our sample size we found some associations at least where FlightPath has shown some abnormalities similar to what other examinations have found as well, whether that’s the SCAT test or the ImPACT test.”

There are other concussion applications commercially available, but Dr. Cross suggests none are as robust as FlightPath.

“There aren't any, as far as I've seen, that use this mixed reality approach to gather the kinds of data that we're gathering. This is very rich data in a very short time in our app. One of the things that makes it so unique and sets it apart is that we get so much data about so many different manifestations of concussion in such a short time.”

Testing is expected to take at least two years. After testing, the app will be submitted to the FDA for clinical approval.


Clinical trial for people who can't sleep with CPAP in progress

Photo: Quin Stevenson/Unsplash
BPT - If you are one of the more than 35 million Americans who are estimated to have obstructive sleep apnea (OSA), you already know how disruptive it can be to your life. While OSA is one of the most common and serious sleep disorders, the condition is widely under-diagnosed, so the number of affected Americans may be far greater.

What is obstructive sleep apnea?

OSA occurs when the muscles in the throat relax during sleep, blocking normal breathing. This can lead to low levels of oxygen in your blood while you sleep and result in poor sleep, fatigue and sleepiness that can negatively impact quality of life for many. In the long term, OSA has also been shown to contribute to high blood pressure, diabetes, cardiovascular disease and stroke.

Most people diagnosed with OSA are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, which can work very well in helping people receive the oxygen they need while they are sleeping. However, because many have difficulty using or tolerating these devices, a significant percentage of the population with OSA remains untreated, undertreated and at risk.

A new option for treating obstructive sleep apnea

Apnimed is a pharmaceutical company working to change the way OSA is treated. The company recently completed a large Phase 2b clinical trial, called MARIPOSA, to study AD109 (an investigational medication which is a single pill taken at bedtime) as a possible treatment for obstructive sleep apnea.

AD109 has the potential to be the first oral medication that treats both the underlying cause of OSA - airway obstruction at night - and improve the daytime symptoms of OSA, such as fatigue. It is designed to treat people with OSA from mild to severe.

Many patients with OSA are unable to adequately treat their condition with existing options, and the team at Apnimed is driven to find new solutions for patients and their doctors to overcome these barriers to treatment. The success of this effort is largely dependent on the dedicated work done by patients and doctors in the community who take part in clinical research.

"MARIPOSA results showed that AD109 improved daytime fatigue, which is an often debilitating effect of poor sleep due to OSA," said Paula Schweitzer, Ph.D., an investigator in the MARIPOSA trial and director of research at St. Luke's Sleep Medicine and Research Center, Chesterfield, Missouri. "For those who cannot tolerate current treatments, AD109 has the potential to be a convenient oral pill that could improve people's quality of life at night and during the daytime as well."

Learn about enrolling in the clinical trial

With the promising results from the MARIPOSA study, a new study is now available for people with OSA.

If you or a loved one has obstructive sleep apnea and you are unable to successfully use or tolerate treatment with a CPAP machine, you could be eligible to enroll in a six-month clinical trial called SynAIRgy.

To learn more about the clinical trial and to enroll, visit: www.SynAIRgyStudy.com.


Stress-free Thanksgiving tips for those short on time this holiday season

While gathering for Thanksgiving is intended to be a joyous occasion, everyone who has hosted the feast knows it can also come with a lot of stress, and expenses.

The good news is that whether you’re a Gen Z-er hosting your first Friendsgiving on a budget or you’re a busy family preparing for guests, there is a lot to be thankful for this year.


Op-Ed |
Tipped wage system isn't working, removing taxes won't save it
Both major presidential candidates have called for eliminating taxes on tips. But that won’t help most restaurant workers.

What will? Replacing the subminimum wages that tipped workers make with one fair wage nationwide.

The federal minimum wage for most workers is just $7.25. But for workers who get tips, employers are allowed to pay them $2.13 an hour. If tips don’t raise your hourly pay to at least the ...
Health & Wellness |
Is it depression, ADHD or bipolar disorder?
Lavender Zarraga, APRN, a behavioral health provider at OSF HealthCare, says it’s not uncommon for her patients to ask for a medication that isn’t the right fit.

The culprit? She says symptoms of common mental health issues like depression, attention deficit hyperactivity disorder (ADHD) and bipolar disorder can overlap. So, it’s important to stay in contact with your provider to make ...